Business Description
Immunic Inc
NAICS : 541714
SIC : 2834
ISIN : US4525EP1011
Total Employee Number:
95Description
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. It operates in one segment which is Life science segment.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 443.3 | |||||
Equity-to-Asset | 0.8 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 37.5 | |||||
3-Year EPS without NRI Growth Rate | 39.1 | |||||
3-Year FCF Growth Rate | 35.4 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 19.44 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 46.35 | |||||
9-Day RSI | 53.5 | |||||
14-Day RSI | 56.01 | |||||
3-1 Month Momentum % | 1.34 | |||||
6-1 Month Momentum % | 81.98 | |||||
12-1 Month Momentum % | 45.44 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 4.92 | |||||
Quick Ratio | 4.92 | |||||
Cash Ratio | 4.86 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -45.2 | |||||
Shareholder Yield % | 0.13 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -283.88 | |||||
ROA % | -154.99 | |||||
ROIC % | -2121.81 | |||||
3-Year ROIIC % | -1046.34 | |||||
ROC (Joel Greenblatt) % | -8152.74 | |||||
ROCE % | -297.16 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 1.34 | |||||
Price-to-Tangible-Book | 1.34 | |||||
EV-to-EBIT | -0.15 | |||||
EV-to-Forward-EBIT | -0.1 | |||||
EV-to-EBITDA | -0.15 | |||||
EV-to-Forward-Revenue | 29.86 | |||||
EV-to-FCF | -0.2 | |||||
| Price-to-Net-Current-Asset-Value | 1.35 | |||||
| Price-to-Net-Cash | 1.37 | |||||
Earnings Yield (Greenblatt) % | -666.67 | |||||
FCF Yield % | -40.21 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:IMUX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Immunic Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -5.08 | ||
| Beta | 1.0167 | ||
| 3-Year Sharpe Ratio | 0.08 | ||
| 3-Year Sortino Ratio | 0.14 | ||
| Volatility % | 97.6 | ||
| 14-Day RSI | 56.01 | ||
| 14-Day ATR ($) | 1.00707 | ||
| 20-Day SMA ($) | 14.36825 | ||
| 12-1 Month Momentum % | 45.44 | ||
| 52-Week Range ($) | 5.062 - 15.84 | ||
| Shares Outstanding (Mil) | 13.62 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Immunic Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Immunic Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-13 | In 127 days | ||
| Second quarter earnings results for 2026 | 2026-08-07 | In 29 days | ||
| General meeting for 2026 | 2026-06-29 09:00 | 15.30 (+2.20%) | ||
| First quarter earnings results for 2026 | 2026-05-13 | 11.90 (-0.75%) | ||
| 0.1:1 Stock Split | 2026-04-27 | 8.80 (-2.21%) | ||
| Guidance call for 2026 | 2026-03-18 16:00 | 12.00 (+4.35%) | ||
| Leerink Partners Global Healthcare Conference | 2026-03-11 10:40 | 12.90 (+0.78%) | ||
| Annual report for 2025 | 2026-02-26 | 9.10 (+0.93%) | ||
| 8th Annual Evercore ISI Healthcare Conference | 2025-12-04 09:35 | 6.50 (-2.99%) | ||
| Third quarter earnings results for 2025 | 2025-11-13 | 7.60 (-3.02%) |
Show
Entries
Immunic Inc Frequently Asked Questions
What is Immunic Inc(IMUX)'s stock price today?
The current price of IMUX is $14.87. The 52 week high of IMUX is $15.84 and 52 week low is $5.06.
When is next earnings date of Immunic Inc(IMUX)?
The next earnings date of Immunic Inc(IMUX) is 2026-08-07 Est..
Does Immunic Inc(IMUX) pay dividends? If so, how much?
Immunic Inc(IMUX) does not pay dividend.
Guru Commentaries on NAS:IMUX
No articles.
Press Release
Articles on Immunic Inc
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers